A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

NCT02881138 | Completed Phase 1

• 1 other identifier: C001 CANCER
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive

Conditions

Solid Tumors

Outcome Measures

Primary Outcomes (2)

• maximal tolerance dose (MTD) of RC48-ADC

  Maximum-tolerated dose (MTD) was defined as the highest dose level at which no more than one of six patients experienced DLT during the DLT assessment window.

  DLT will be evaluated on 28 days of observation period

• AEs

  The drug safety was assessed by investigator(s) according to NCI-CTCAE v4.0

  Estimated 2 years

Secondary Outcomes (3)

• Cmax

  Estimated 2 years

• AUC

  Estimated 2 years

• Tmax

  Estimated 2 years

Study Arms (1)

RC48-ADC

EXPERIMENTAL

Participants will be allocated to one of the following dose groups: 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC48-ADC followed by 28 days of dose limited toxicity (DLT) observation period.

Drug: RC48-ADC

Interventions

RC48-ADC DRUG

RC48-ADC

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed informed consent form;
• Aged 18-65 years;
• ECOG physical condition is 0 or 1;
• Life expectancy greater than 12 weeks;
• Diagnosed with histologically or cytologically-confirmed, standard treatment is ineffective (disease progresses after treatment) or HER2-positive, locally advanced or metastatic malignant solid tumor patients who cannot tolerate standard therapy, cannot receive or do not have standard therapy;
• Human epidermal growth factor receptor 2 (HER2)-positive as measured either by immunohistochemistry (IHC 2+ and by fluorescence in situ hybridization (FISH) or by immunohistochemistry (3+);
• Patients with measurable and appreciable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1);
• Adequate organ function as defined by the following criteria:
• absolute neutrophil count(ANC) \>= 1.5 x 10(9)/L;
• platelets\>=100\*10(9)/L;
• Total serum bilirubin \<=1.5\*ULN;
• serum aspartate transaminase (AST) and serum alanine transaminase (ALT) \<=2.5\*upper limit of normal (ULN), or AST and ALT\<=5\*ULN with hepatic metastasis;
• Serum creatinine clearance rate \>=45ml/min;
• international normalized ratio (INR) and activated partial thromboplastin time (APTT) must be less than or equal to 1.5 times the upper limit of the normal range (ULN);
• Women of child-bearing potential and men must agree to use adequate contraception (e.g. condoms, implants, injectables, combined oral contraceptives, some intrauterine devices \[IUDs\], complete sexual abstinence, or sterilized partner) prior to study entry and during the period of therapy and for 30 days after the last dose of study drug;

You may not qualify if:

• Current pregnancy or lactation;
• Received anti-tumor treatment 4 weeks before study administration, including chemotherapy, radiotherapy, hormone therapy, biological therapy or immunotherapy, except the following: Gonadotropin-releasing hormone (GnRH) antagonistic therapy for prostate cancer and Hormone replacement therapy;
• Major surgery within 4 weeks of first dose of study drug and not fully recovered;
• Receiving palliative radiation therapy for bone metastases if administered \<= 2 weeks prior to first study treatment;
• Toxicity of previous anti-tumor treatment has not recovered to CTCAE \[version 4.0\] 0-1 (with exception of alopecia);
• Participated in other clinical drug studies within 4 weeks;
• Hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs;
• According to the judgment of the investigator, a clinically significant active infection;
• A history of immunodeficiency, including a positive HIV test, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
• Uncontrollable systemic diseases including diabetes, hypertension, lung Fibrosis, acute lung disease, interstitial lung disease, etc.;
• Congestive heart failure with grade 2 or higher (including grade 2) by the New York Institute of Cardiology (NYHA) of the United States in the history of diseases such as acute myocardial infarction, unstable angina, stroke, or transient ischemic attack within 6 months before enrollment;
• Insufficient adherence to participate in this clinical study;
• Treated with Herceptin (Trastuzumab) within 60 days before the trial;
• Have received systemic steroid therapy for a long time ( short-term users who discontinue medication\> 2 weeks can be selected);
• Uncontrolled primary or metastatic tumor of brain;

Sponsors & Collaborators

• RemeGen Co., Ltd.: lead

Study Sites (1)

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China

Location

Study Officials

• Binghe Xu

  Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 20, 2016
• First Posted: August 26, 2016
• Study Start: March 1, 2016
• Primary Completion: April 30, 2020
• Study Completion: July 15, 2020
• Last Updated: July 30, 2020

Record last verified: 2020-02

Locations

CN (1)